Our pipeline
Advancing immunotherapies for genetically defined cancers.
Haptena develops innovative immunotherapy programs for cancers driven by specific genetic alterations.
We believe that a deeper understanding of oncogenic pathways can unlock new immune-based strategies.
Our initial focus is on cancers with KRAS G12C mutations.
In parallel, we are advancing additional discovery programs across other genetically defined tumors, with the goal of building a diversified and expandable immuno-oncology pipeline.
Deep biological insight to exploit resistance
Haptena’s scientific foundation lies in a deep mechanistic understanding of how tumor cells adapt under therapeutic pressure. By studying how cancer cells respond to targeted therapies, how the tumor evolves resistance, Haptena identified vulnerabilities that can be turned into precise therapeutic targets.
This biology-first, mechanism-driven framework allows the company to develop therapeutic strategies that are precisely aligned with the genetic context of each tumor.
Integration of targeted inhibition and immune activation
Haptena brings together two traditionally separate therapeutic principles: targeted therapies and immunotherapies. Relying on the synergy of genetic inhibition and immune activation, Haptena aims to create a controllable system with the potential for higher efficacy and improved safety.
This integrated approach aims to deliver deeper and more durable responses in tumors, such as KRAS-mutant cancers.